1.29
-0.09(-6.52%)
Currency In USD
| Previous Close | 1.38 |
| Open | 1.37 |
| Day High | 1.42 |
| Day Low | 1.27 |
| 52-Week High | 10.62 |
| 52-Week Low | 1.2 |
| Volume | 10.19M |
| Average Volume | 4.72M |
| Market Cap | 150.1M |
| PE | -0.91 |
| EPS | -1.42 |
| Moving Average 50 Days | 8.32 |
| Moving Average 200 Days | 6.15 |
| Change | -0.09 |
If you invested $1000 in Applied Therapeutics, Inc. (APLT) since IPO date, it would be worth $137.23 as of December 05, 2024 at a share price of $1.29. Whereas If you bought $1000 worth of Applied Therapeutics, Inc. (APLT) shares 3 years ago, it would be worth $125.24 as of December 05, 2024 at a share price of $1.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
GlobeNewswire Inc.
Nov 27, 2024 9:10 PM GMT
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced that the U.S. Food and Drug Administration (FDA) ha
Applied Therapeutics Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 07, 2024 12:00 PM GMT
- NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for govorestat for the treatment of SORD
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
GlobeNewswire Inc.
Nov 05, 2024 12:00 PM GMT
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medica